CAR T-cell therapy is a revolutionary cancer treatment poised for FDA approval.

After decades of research, CAR T-cell therapy, a so-called “living drug” that genetically alters a patient’s own immune cells to kill cancer, is poised for FDA approval in pediatric leukemia, with other approvals expected to follow. Hailed as a revolution in cancer treatment, New York-Presbyterian/Columbia University is among the medical centers that plans to offer CART-cell therapy to patients. HICCC member Dr. Prakash Satwani, Associate Professor of Pediatrics at CUMC and pediatric hematologist/oncologist at NYP/CUMC, spoke with USA Today and Targeted Oncology about the promise and the challenges of this breakthrough in cancer treatment.